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MIC increases. Positions 965–967 correspond to the
triple-base-pair mutation involved in the high-level tetracycline
resistance in H. pylori,2 whereas nucleotide 1054 contacts the
A-site tRNA.6 In contrast, the G346A mutation is located in a 16S
rRNA region not closely associated with tetracycline binding.
For M. pneumoniae, two mutations were found in the broth-
selected mutants and were associated with 2- to 16-fold increases
in MICs of the three tetracyclines studied, in comparison with
those of the parental strain FH. The two mutations described for
this species, G1193A and T968C, are located very close to or
contact the primary tetracycline binding site, respectively.
In summary, this is the first description of mutations in 16S
rRNA associated with decreased susceptibility to tetracyclines in
human mycoplasmas. However, what real effect these new
mutations have on the tetracycline susceptibility of both myco-
plasmas has yet to be determined.
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Sir,
The current emergence and dissemination of clavulanic acid-
inhibited, extended-spectrum b-lactamase (ESBL)-producing
Enterobacteriaceae represent a global threat, as they are difficult
to trace and eradicate, and cause both nosocomial and
community-acquired infections.1 Although the unexplained
worldwide escalation of CTX-M-type enzymes is of major
concern, other types of ESBLs may be prevalent in more
restricted geographical areas. The ESBL PER-1 has been identi-
fied in several Gram-negative species including Salmonella
typhimurium, Pseudomonas aeruginosa and Acinetobacter
baumannii.2 This ESBL determinant has been identified in
several countries such as France, Italy, Poland and South Korea
and is particularly widespread in Turkey.2
We report here a multidrug-resistant Providencia stuartii
isolate, which was recovered in 2004 from a 60-year-old patient
who had a femur head prosthesis implantation at the University
Hospital Pristina, Kosovo. He subsequently developed a chronic
infection, fistulations occurred and he was transferred to the
University Medical Clinic of Orthopaedic Surgery, Liestal,
Switzerland, where his femur head was removed. Cultures made
from intra-operative biopsies yielded oxacillin-susceptible
Staphylococcus aureus, Enterococcus faecium and P. stuartii iso-
lates; the latter isolate was identified with the API32GN system
(bioMe´rieux, Marcy l’E´toile, France). Disc diffusion and broth
microdilution methods were used to determine its antibiotic sus-
ceptibility and results were interpreted according to CLSI criteria.
P. stuartii isolate 166 was resistant to multiple antibiotics includ-
ing oxyimino-cephalosporins, fluoroquinolones, chloramphenicol,
tetracycline, trimethoprim, aminoglycosides (except amikacin)
and colistin, but it remained susceptible to cephamycins and car-
bapenems. Synergy tests performed with discs containing ticarcil-
lin/clavulanic acid and either ceftazidime or cefepime indicated
production of an ESBL. PCR with primers specific for known
ESBL genes2 identified blaPER-1, and PCR mapping showed this
to be part of a Tn1213 composite transposon.3 Plasmid-mediated
Qnr-type determinants have been associated with ESBL genes,
but isolate 166 lacked known Qnr-encoding genes.4 Conjugation
studies, with ceftazidime selection and Escherichia coli J53
(azide-resistant) as the recipient, showed that the blaPER-1 gene
was located on a 150 kb plasmid, which also conferred resistance
to chloramphenicol, trimethoprim, aminoglycosides (except ami-
kacin) and sulphonamides.
The patient was treated for 6 weeks in Switzerland with imi-
penem and vancomycin and recovered, but further follow-up
was not possible because the patient returned to Kosovo.
There are no epidemiological data regarding ESBLs available
for Kosovo. A survey recently performed in Bosnia and
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Herzegovina identified SHV-5 producers among ESBL-positive
enterobacterial isolates.5 PER-1 ESBL has been identified in
A. baumannii and P. aeruginosa in Turkey and Romania, and in
P. stuartii in Italy.6 This report of PER-1 in an enterobacterial
isolate from Kosovo may indicate that the blaPER-1 gene has
spread in South Eastern Europe.
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Sir,
The population of India of over one billion represents a poten-
tially vast reservoir of antimicrobial resistance genes including
those encoding extended-spectrum b-lactamases (ESBLs).
Occurrence of ESBL-producing Enterobacteriaceae has been
described in India mostly using phenotypic detection methods
alone. The present study was conducted to identify the occur-
rence of ESBL genes in urinary isolates of Klebsiella pneumo-
niae collected in Southern India.
The study was conducted at two hospitals, one in Gulbarga
and the other in Raichur, between July 2005 and March 2006.
The two cities are ~150 km away from each other and have
populations of ~440 000 and 160 000, respectively. A total of
1288 non-duplicate urine specimens were collected from 642
inpatients and 646 outpatients. K. pneumoniae was identified by
standard biochemical tests including citrate, urease, indole,
Voges–Proskauer, glucose and inositol. As a result, K. pneumo-
niae was recovered from 270 of 1288 urinary specimens. Among
them, 115 (43%) were from inpatients and 155 (57%) were from
outpatients. ESBL production was confirmed in 260 (96%) iso-
lates using the disc method defined by the CLSI (2007). All
these isolates produced 5 mm increase in zone diameters with
either cefotaxime or ceftazidime discs when clavulanic acid was
added. They represented 95% and 97% of the inpatient and out-
patient isolates, respectively. Of those, 255 isolates were resist-
ant to cefotaxime and were assigned to phenotypic Group I,
which was further classified into subgroups depending on sus-
ceptibility to ceftazidime and cefepime (Table 1). Another five
isolates with resistance to ceftazidime but not to cefotaxime
were assigned to phenotypic Group II. The remaining 10
non-ESBL-producing isolates susceptible to both cefotaxime and
ceftazidime were assigned to phenotypic Group III. For
non-b-lactam antimicrobials, 92% and 95% of the inpatient and
outpatient isolates were resistant to ciprofloxacin, respectively.
High rates of resistance to gentamicin (79% and 83% in inpatient
and outpatient isolates, respectively) and amikacin (66% and 69%
in inpatient and outpatient isolates, respectively) were also
observed. Resistance to chloramphenicol, which is still commonly
prescribed for infections caused by K. pneumoniae in India, was
observed in 90% and 92% of the inpatient and outpatient isolates,
respectively. All the study isolates were susceptible to ertapenem,
except for one isolate which was intermediately resistant. No
resistance to imipenem was identified.
A total of 35 isolates from all phenotypic groups and sub-
groups were subjected to PFGE analysis using restriction
enzyme XbaI (New England Biolabs, Ipswich, MA, USA) and
CHEF III DR electrophoresis system (Bio-Rad, Hercules, CA,
USA). Forty-five percent of the isolates in the phenotypic Group
I that were examined by PFGE belonged to pulsotype A
(Table 1). This pulsotype was commonly observed regardless of
the source hospitals or the patient locations. The isolates in the
phenotypic Group II belonged to pulsotype D. A total of 60 iso-
lates from various pulsotypes were then subjected to PCR analy-
sis for the detection of blaTEM, blaSHV and blaCTX-M, as
described previously.1,2 All the isolates belonging to the
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